Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...

Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...